| An overview of alternative splicing defects implicated in myotonic dystrophy type I A López-Martínez, P Soblechero-Martín, L de-la-Puente-Ovejero, ... Genes 11 (9), 1109, 2020 | 85 | 2020 |
| Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies P Soblechero‐Martín, A López‐Martínez, L de la Puente‐Ovejero, ... Neuropathology and Applied Neurobiology 47 (6), 711-723, 2021 | 29 | 2021 |
| Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation S García-Alonso, P Mesa, L de la Puente Ovejero, G Aizpurua, ... Molecular cell 82 (18), 3438-3452. e8, 2022 | 19 | 2022 |
| Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening P Soblechero-Martín, E Albiasu-Arteta, A Anton-Martinez, ... Scientific Reports 11 (1), 18188, 2021 | 11 | 2021 |
| Building insights into CDC37-RAF1 interaction: an opportunity for design new strategies to treat KRAS driven tumors. L De-la-Puente-Ovejero, G Aizpurua, C Gonzalez Lechuga, P Mesa, ... ibjournals 1 (0001-e0049), e00037, 2022 | | 2022 |
| In vitro study of cellular, molecular and functional mechanisms underlying pelvic floor disorders J Medina-Polo, AI Flores, MJ Perez-Lorenzo, A Alcazar-Garrido, ... European Urology Open Science 19, e1614, 2020 | | 2020 |
